GO
Loading...

Closing Bell

More

  • Ackman front-running Valeant's bid?     Tuesday, 22 Apr 2014 | 4:12 PM ET

    Providing insight on Bill Ackman and Valeant's proposed takeover of Allergan, with former SEC chairman Harvey Pitt and CNBC's Kate Kelly.

  • Be prepared for lower returns, says Jack Bogle Tuesday, 22 Apr 2014 | 3:19 PM ET
    Jack Bogle

    And it all has to do with how earnings are valued, the founder of the Vanguard group told CNBC.

  • CEO pay is out of line: Jesse Ventura Tuesday, 22 Apr 2014 | 5:42 PM ET
    Jesse Ventura

    CEOs and physical laborers should be closer in pay, former Minnesota Gov. Jesse Ventura told CNBC on Tuesday.

  • Gilead earnings blowout: Pro     Tuesday, 22 Apr 2014 | 4:09 PM ET

    Providing instant analysis to Gilead and Amgen's quarterly numbers, with David Nelson, Belpointe Asset Management, and CNBC's Sharon Epperson and Kate Kelly.

  • Big Q1 for Gilead     Tuesday, 22 Apr 2014 | 4:07 PM ET

    Gilead is reporting Q1 EPS of $1.48 adj. on revenues of $5.00 billion, with CNBC's Meg Tirrell.

  • Show me accretive pharma: O'Leary     Tuesday, 22 Apr 2014 | 4:06 PM ET

    "Shark Tank" investor Kevin O'Leary discusses recent mergers between pharmaceutical companies.

  • Amgen Q1 earnings miss     Tuesday, 22 Apr 2014 | 4:06 PM ET

    Amgen is reporting Q1 EPS of $1.87 ex-items on revenues of $4.52 billion, with CNBC's Meg Tirrell.

  • AT&T beats on earnings     Tuesday, 22 Apr 2014 | 4:05 PM ET

    AT&T is reporting Q1 EPS of $0.71 on revenue of $32.5 billion, with CNBC's Dominic Chu.

  • Technical work suggests down draft: Pro     Tuesday, 22 Apr 2014 | 3:58 PM ET

    Stephen Wood, Russell Investments chief market strategist, and Terry Dolan, Benjamin & Jerold Brokerage CEO, discuss if the market is approaching a double top.

  • No rhyme or reason to rally: CEO     Tuesday, 22 Apr 2014 | 3:49 PM ET

    Discussing their investment strategies in this market rally, with Stephen Wood, Russell Investments chief market strategist, and Terry Dolan Benjamin & Jerold Brokerage CEO.

  • Biotech earnings: All eyes on Gilead     Tuesday, 22 Apr 2014 | 3:45 PM ET

    CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.

  • Eco-investing for 'green' returns     Tuesday, 22 Apr 2014 | 3:39 PM ET

    Leslie Samuelrich, Green Century Capital Management president, explains how investors can capitalize in ways that are "green" and "friendly" to the environment and shares her best eco-friendly buys.

  • Should shareholders be satisfied with Citi?     Tuesday, 22 Apr 2014 | 3:28 PM ET

    Jeffery Harte, Sandler O'Neill principal, weighs in on the recent turmoil at Citigroup, including fraud at its Mexican operations. CNBC's Kayla Tausche provides insight.

  • Citi trying to become safer: Chairman     Tuesday, 22 Apr 2014 | 3:26 PM ET

    CNBC's Kayla Tausche reports from Citigroup's annual shareholder meeting where top shareholders faced executives for the first time since the bank failed the Fed's stress test.

  • Jack Bogle: HFT here to stay     Tuesday, 22 Apr 2014 | 3:17 PM ET

    Vanguard founder Jack Bogle, discusses long-term investing in equities and shares is thoughts on high-frequency trading.

  • David Einhorn warns of tech bubble     Tuesday, 22 Apr 2014 | 3:14 PM ET

    Hedge fund manager David Einhorn has sent out Greenlight Capital's quarterly investor letter, reports CNBC's Dominic Chu.

  • Closing Bell Exchange: Justifying market moves     Tuesday, 22 Apr 2014 | 3:02 PM ET

    Discussing the market rally and if a bigger pullback will strike, with Kenny Polcari, O'Neil Securities; Stephen Wood, Russell Investments, Chris Hobart, Hobart Financial Group; and Rob Morgan, V2V Associates.

  • Best (and worst) jobs of 2014     Monday, 21 Apr 2014 | 4:51 PM ET

    CareerCast revealed their annual ranking of the 10 best and worst jobs for 2014. CNBC's Seema Mody reports.

  • Lumberjack vs. mathematician     Monday, 21 Apr 2014 | 4:51 PM ET

    With CareerCast naming the best and worst jobs for 2014, Lee LeCaptain, lumberjack, and Jerrod Ankenmen, mathematician, make the case for their professions.

  • Ackman's pursuit of Allergan     Monday, 21 Apr 2014 | 4:45 PM ET

    Discussing Bill Ackman's partnership with Valeant to pursue a takeover of Allergan, with CNBC contributor Herb Greenberg and CNBC's Meg Tirrell.

About Closing Bell

  • Anything can happen between the bells of the trading day. But what happens during the last hour could be what matters most. CNBC's "Closing Bell" guides you through the most important hour of the trading day. The show takes a close-up look at how the markets are moving, what's driving them and how investors are reacting. Live coverage includes reports from the Chicago Board of Trade, New York Mercantile Exchange, NASDAQ and the NYSE. Analysts, money managers and CEOs explain their strategies, share opinions, and provide an inside perspective on breaking news stories. In addition, "Closing Bell" provides instant analysis of corporate profit reports, as soon as they break, during the quarterly earning seasons. Features include interviews with entrepreneurs, plus an inside-look at how executives and high-net-worth individuals spend their time and money.

Contact Closing Bell

  • Showtimes

    United States
    Monday - Friday 3:00P ET
    Europe
    Monday - Saturday 21:00 CET
    Asia
    Tuesday - Saturday 03:00 SIN/HK
    Australia
    Tuesday - Saturday 05:00 SYD
    New Zealand
    Tuesday - Saturday 07:00 NZ

 

  • With almost 30 years experience in business television, Bill Griffeth is co-anchor of the 3 p.m. ET hour of CNBC's "Closing Bell."

  • Kelly Evans

    Kelly Evans is co-anchor of CNBC's "Closing Bell."

Follow Closing Bell